bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析

【英語タイトル】bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C8763)・商品コード:DATA904C8763
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:46
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

bluebird bio Inc (BLUE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc Key Recent Developments

Oct 05,2018: bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia
Oct 05,2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia
Oct 01,2018: bluebird bio to Present at the LEERINK Partners Roundtable Series Rare Disease Immuno-Oncology
Aug 24,2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies
Aug 08,2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
bluebird bio Inc – Key Facts 6
bluebird bio Inc – Key Employees 7
bluebird bio Inc – Key Employee Biographies 8
bluebird bio Inc – Major Products and Services 10
bluebird bio Inc – History 11
bluebird bio Inc – Company Statement 13
bluebird bio Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
bluebird bio Inc – Business Description 16
bluebird bio Inc – Corporate Strategy 17
bluebird bio Inc – SWOT Analysis 18
SWOT Analysis – Overview 18
bluebird bio Inc – Strengths 18
bluebird bio Inc – Weaknesses 19
bluebird bio Inc – Opportunities 20
bluebird bio Inc – Threats 21
bluebird bio Inc – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
bluebird bio Inc, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Oct 05, 2018: bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia 32
Oct 05, 2018: bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia 33
Oct 05, 2018: bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia 34
Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 35
Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 36
Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 37
Aug 24, 2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies 38
Aug 24, 2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies 39
Aug 08, 2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies 40
Aug 08, 2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies 41
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
bluebird bio Inc, Key Facts 6
bluebird bio Inc, Key Employees 7
bluebird bio Inc, Key Employee Biographies 8
bluebird bio Inc, Major Products and Services 10
bluebird bio Inc, History 11
bluebird bio Inc, Other Locations 14
bluebird bio Inc, Subsidiaries 14
bluebird bio Inc, Key Competitors 22
bluebird bio Inc, Ratios based on current share price 23
bluebird bio Inc, Annual Ratios 24
bluebird bio Inc, Annual Ratios (Cont...1) 25
bluebird bio Inc, Interim Ratios 27
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
bluebird bio Inc, Recent Deals Summary 31
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

List of Figures
bluebird bio Inc, Performance Chart (2013 - 2017) 26
bluebird bio Inc, Ratio Charts 28
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

★調査レポート[bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析] (コード:DATA904C8763)販売に関する免責事項を必ずご確認ください。
★調査レポート[bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆